ライフサイエンスコーパス: cerebrovascular event

1 s, respectively, had been hospitalized for a cerebrovascular event.

2 for acute coronary syndromes after a recent cerebrovascular event.

3 iffer in women who have experienced a recent cerebrovascular event.

4 articularly at risk of hospitalization for a cerebrovascular event.

5 r risk for an acute major adverse cardiac or cerebrovascular event.

6 Major adverse cardiovascular or cerebrovascular events.

7 ined by magnetic resonance imaging (MRI) for cerebrovascular events.

8 sis (PCI arm), and major adverse cardiac and cerebrovascular events.

9 in asymptomatic group experienced recurrent cerebrovascular events.

10 s thrombosis are less common causes of acute cerebrovascular events.

11 are associated with increased risk of future cerebrovascular events.

12 t studies have raised concerns about adverse cerebrovascular events.

13 , venous thromboembolic events, and ischemic cerebrovascular events.

14 Presence of IPH on MRI strongly predicts cerebrovascular events.

15 dentifies high-risk features associated with cerebrovascular events.

16 quent increases in the rates of coronary and cerebrovascular events.

17 oramen ovale (PFO) are at risk for recurrent cerebrovascular events.

18 and an increased risk of cardiovascular and cerebrovascular events.

19 carotid restenosis on the risk of recurrent cerebrovascular events.

20 atherosclerosis, they are poor predictors of cerebrovascular events.

21 laque hemorrhage as a predictor of recurrent cerebrovascular events.

22 ) were all predictive of subsequent maternal cerebrovascular events.

23 has been associated with potentially serious cerebrovascular events.

24 es are not associated with future cardiac or cerebrovascular events.

25 ependently associated with either cardiac or cerebrovascular events.

26 h has been implicated in atherosclerosis and cerebrovascular events.

27 investigate the association between CED and cerebrovascular events.

28 ndently associated with an increased risk of cerebrovascular events.

29 ssive surveillance, 802 were validated to be cerebrovascular events.

30 tification of high-risk plaques that lead to cerebrovascular events.

31 fficacy, drug cost, and rates of cardiac and cerebrovascular events.

32 ngenital heart disease are at risk of having cerebrovascular events.

33 in terms of major adverse cardiovascular and cerebrovascular events.

34 be a marker of increased risk for recurrent cerebrovascular events.

35 sociated with an increased risk of recurrent cerebrovascular events.

36 ocardial infarction are at increased risk of cerebrovascular events.

37 se and increased risk for cardiovascular and cerebrovascular events.

38 thrombosis (0.44%; range, 0.28%-0.68%), and cerebrovascular events (0.32%; range, 0.18%-0.53%) were

39 Twenty-two patients (13.6%) had 29 cerebrovascular events (1/100 patient-years).

40 of cell therapy on major adverse cardiac and cerebrovascular events (14.0% versus 16.3%; hazard ratio

41 al, 1.32-1.90) and major adverse cardiac and cerebrovascular events (2.62; 2.28-3.01; all P<0.001).

42 , there were 36 deaths (2.2%) and 48 adverse cerebrovascular events (2.9%) in the postoperative hospi

43 The commonest of these were first cerebrovascular events, 205 (CI: 183, 230); shingles, 14

44 patients were more likely to have had prior cerebrovascular events (22% versus 15%; P=0.0003) and me

45 elated to the incidence of both coronary and cerebrovascular events, 24-hour ambulatory diastolic blo

46 ardial infarction (35 523 individuals), 6 on cerebrovascular events (27 689 individuals), and 5 on al

47 <0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.7

48 , P=0.003), major adverse cardiovascular and cerebrovascular events (4.6% versus 5.7%, P=0.007), and

49 0.034), and major adverse cardiovascular or cerebrovascular events (40.2% vs. 47.9%, respectively; p

50 782 cancer survivors were hospitalized for a cerebrovascular event-40% higher than expected (SHR=1.4,

51 r events end point, including death, MI, and cerebrovascular event (5.0% versus 2.6% in men; 5.1% ver

52 was associated with a higher rate of 30-day cerebrovascular events (7.1% versus 0.4%; P=0.030).

53 Those with CM-associated cerebrovascular events (8%) may benefit from short-term

54 y; p < 0.001), and major adverse cardiac and cerebrovascular events (8.7% vs. 23.9%, respectively; p

55 -year freedom from major adverse cardiac and cerebrovascular events (89.4% versus 71.2%; 81.9% versus

56 roups in the number of combined coronary and cerebrovascular events: 96 (3.7%) with placebo, 82 (3.2%

57 ombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial

58 Coronary or cerebrovascular events (adjusted for age, gender, tradit

59 boembolic events; HR 1.5, 95% CI 0.7-3.2 for cerebrovascular events) after adjusting for age, sex, bo

60 vestigate the risks of hospitalization for a cerebrovascular event among 5-year survivors of cancer d

61 evaluate the risks of hospitalization for a cerebrovascular event among long-term survivors of teena

62 The risk of a cerebrovascular event among subjects with ASA was nearly

63 nt for the secondary prevention of recurrent cerebrovascular events among patients with PFO-related t

64 tion of long-term risk of cardiovascular and cerebrovascular events and death.

65 eduction in major adverse cardiovascular and cerebrovascular events and increased bleeding.

66 may be responsible for the increased risk of cerebrovascular events and neurodegenerative disorders i

67 the rate of major adverse cardiovascular and cerebrovascular events and no increase in the risk of st

68 The incidence of cerebrovascular events and peripheral vascular disease e

69 alysis was used to estimate CVE (cardiac and cerebrovascular events) and all-cause mortality hazard r

70 nary heart disease event, 17,822 had a first cerebrovascular event, and 14,550 had a first venous thr

71 d their components of cardiovascular events, cerebrovascular events, and 30-day mortality.

72 here were 44 (11%) cardiac events, 18 (4.5%) cerebrovascular events, and 41 deaths (10.3%).

73 of TAVR candidates, led to a higher rate of cerebrovascular events, and accounted for a third of arr

74 infarction, major adverse cardiovascular and cerebrovascular events, and Global Utilization of Strept

75 The cumulative incidence of cerebrovascular events, and rehospitalization due to car

76 cidence rates of peripheral arterial events, cerebrovascular events, and venous thromboembolic events

77 Cerebrovascular events are a serious complication of cya

78 However, bleeding and cerebrovascular events are common; these may be modifiab

79 g profiles of antipsychotics and the risk of cerebrovascular events are unclear.

80 the rate of early major adverse cardiac and cerebrovascular events as well as long-term survival.

81 a include an increased risk of mortality and cerebrovascular events, as well as metabolic effects, ex

82 ere excluded, there was an increased risk of cerebrovascular events associated with microcytosis (p <

83 the occurrence of major adverse cardiac and cerebrovascular event at 6 months.

84 patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percuta

85 yocardial infarction, revascularization, and cerebrovascular events at 12 months.

86 e early events and major adverse cardiac and cerebrovascular events at 3 years.

87 bined incidence of major adverse cardiac and cerebrovascular events at 30 days after intervention, in

88 to compare major adverse cardiovascular and cerebrovascular events at 30 days and 1 year between pat

89 er rates of major adverse cardiovascular and cerebrovascular events at 7 years.

90 n the subgroup of patients with a history of cerebrovascular events at least 1 year prior to randomiz

91 dent predictors of major adverse cardiac and cerebrovascular events at long-term follow-up.

92 mptomatic, 41 urgent, and 24 patients with a cerebrovascular event between 5 and 180 days of the caro

93 group, there was no difference in recurrent cerebrovascular events between DWI+ and DWI- patients.

94 xhibited a positive linear relationship with cerebrovascular events but a curvilinear relationship wi

95 CIP-BB measure was associated with increased cerebrovascular events but not improved cardiovascular e

96 ombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increa

97 eenage and young adult cancer are at risk of cerebrovascular events, but the magnitude of and extent

98 hibitors and the hazard of cardiovascular or cerebrovascular events, but the use of antiretroviral dr

99 mg/day atorvastatin reduces both stroke and cerebrovascular events by an additional 20% to 25% compa

100 cardial infarction [major adverse cardiac or cerebrovascular event] by day 30 plus ipsilateral stroke

101 During a median follow-up of 5.1 years, cerebrovascular events (cerebrovascular disease-related

102 y, only patient age (P=0.012), but not prior cerebrovascular events, cognitive status, direct TAVI, c

103 ll events together or for cardiovascular and cerebrovascular events combined.

104 l/L) had an adjusted 2.6-fold higher risk of cerebrovascular events compared to those in the highest

105 Relative incidence of cerebrovascular events compared with coronary events was

106 Presentation of cerebrovascular event complicated with out-of-hospital c

107 We evaluated incidence of cerebrovascular events consistent with stroke or transie

108 Recurrent cerebrovascular events constitute an estimated 200,000 o

109 nt (nonfatal myocardial infarction, nonfatal cerebrovascular event, coronary revascularization, or ca

110 ts (nonfatal myocardial infarction, nonfatal cerebrovascular event, coronary revascularization, or ca

111 replacement (TAVR) patients at high risk for cerebrovascular events (CVE) is of major clinical releva

112 hard, patient-centered outcomes of death and cerebrovascular events (CVEs) after heart rhythm disorde

113 predictive factors, and prognostic value of cerebrovascular events (CVEs) after transcatheter aortic

114 aterals influenced the risk of recurrence of cerebrovascular events (CVEs: stroke or transient ischem

115 roup differences in major adverse cardiac or cerebrovascular events, deaths, readmissions, functional

116 tissue plasminogen activator (tPA) following cerebrovascular events demonstrates that tPA also plays

117 By principal management strategy, cerebrovascular events developed in 2.0%, 14.9%, and 1.9

118 -cause mortality, cardiovascular disease and cerebrovascular events, diabetes, cognitive impairment,

119 death, dialysis, myocardial infarction, and cerebrovascular events did not differ significantly at 3

120 nt mortality and nonfatal cardiovascular and cerebrovascular events for those with ST-segment-elevati

121 High-risk patients with Acute Non-disabling Cerebrovascular Events), for efficacy and safety outcome

122 Low homoarginine is strongly associated with cerebrovascular events, graft loss and progression of ki

123 domized patients, 1270 patients (5.1%) had a cerebrovascular event >1 year old, including 650 assigne

124 Patients who had a cerebrovascular event had a significantly increased tend

125 All patients who had a cerebrovascular event had developed > or = 1 risk factor

126 in the 80-mg arm experienced a reduction in cerebrovascular events (hazard ratio 0.77, 95% CI 0.64 t

127 Secondary outcomes were arrhythmia, cerebrovascular events, hemorrhagic stroke, ischemic str

128 e was no association of SW with the risk for cerebrovascular events (HR 1.76, 95% CI 0.45-7.01).

129 nd points included major adverse cardiac and cerebrovascular events (ie, death from any cause, stroke

130 in improved major adverse cardiovascular and cerebrovascular event in patients with 2- and 3-vessel c

131 difference between those with and without a cerebrovascular event in terms of age, smoking history,

132 zard ratio, 0.32; 95% CI, 0.20 to 0.54), and cerebrovascular events in 0 and 4 patients (0 vs. 0.7%).

133 ambient air pollution and risk for ischemic cerebrovascular events in a US community.

134 ht to determine the frequency of spontaneous cerebrovascular events in adult patients with cyanotic c

135 , but MBL-deficient genotypes were not, with cerebrovascular events in Caucasians being the exception

136 id stenting has an increased risk of adverse cerebrovascular events in elderly patients but mortality

137 fficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or yo

138 that HMG-CoA reductase inhibition may reduce cerebrovascular events in patients with prevalent corona

139 e incidence, predictors, and implications of cerebrovascular events in patients with ST-segment-eleva

140 There was a nonsignificant greater rate of cerebrovascular events in PD patients.

141 is not an independent risk factor for future cerebrovascular events in the general population.

142 There were no major adverse cardiac and cerebrovascular events in the hospital or at 3-month fol

143 umber of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group.

144 We describe an analysis of cerebrovascular events in the Treating to New Targets st

145 We evaluated the risk of coronary and cerebrovascular events in the Women's Health Initiative

146 een shown to predict both cardiovascular and cerebrovascular events in various patient populations, i

147 Older age, previous cerebrovascular event, in-hospital coronary artery bypas

148 e of a composite of major adverse cardiac or cerebrovascular events, in functional status, or in qual

149 edom from combined major adverse cardiac and cerebrovascular events (including all-cause death, AMI r

150 nsion, alcoholic cardiomyopathy, cancer, and cerebrovascular events, including cerebrovascular hemorr

151 identify all women aged 12 to 55 years with cerebrovascular events, including transient ischemic att

152 l infarction, coronary revascularization, or cerebrovascular events) independently of each other, wit

153 ed death, especially with cardiovascular and cerebrovascular events, independently of other prognosti

154 f gender difference and estrogen in ischemic cerebrovascular events is controversial.

155 n coronary endothelial dysfunction (CED) and cerebrovascular events is unknown.

156 associated with coronary artery disease) and cerebrovascular events (ischemic fatal and non-fatal str

157 The 30-day major adverse cardiac and cerebrovascular event (MACCE) rate for CABG and PCI was

158 ary endpoint was a major adverse cardiac and cerebrovascular event (MACCE), which was defined as comp

159 rimary outcome was major adverse cardiac and cerebrovascular events (MACCE) (i.e., death, stroke, myo

160 the risk of major adverse cardiovascular and cerebrovascular events (MACCE) among those with AF.

161 tin use and major adverse cardiovascular and cerebrovascular events (MACCE) and amputation-free survi

162 e of perioperative major adverse cardiac and cerebrovascular events (MACCE) and bleeding and its rela

163 Major adverse cardiovascular and cerebrovascular events (MACCE) are a significant source

164 from any cause and major adverse cardiac and cerebrovascular events (MACCE) at 1 year.

165 activity, and risk of major adverse cardiac/cerebrovascular events (MACCE) at 1 year: myocardial inf

166 point consisted of major adverse cardiac and cerebrovascular events (MACCE) at 30 days, and the prima

167 rimary endpoint was major adverse cardiac or cerebrovascular events (MACCE), a composite of all-cause

168 ing, or death), and major adverse cardiac or cerebrovascular events (MACCE).

169 ombosis and major adverse cardiovascular and cerebrovascular events (MACCE).

170 Mortality and major adverse cardiac and cerebrovascular events (MACCE, defined as all-cause mort

171 e primary endpoint (major adverse cardiac or cerebrovascular events [MACCE]) was a composite of all-c

172 cardiac endpoint (major adverse cardiac and cerebrovascular events [MACCE]), and quality of life (QO

173 outcomes of major adverse cardiovascular or cerebrovascular events (MACCEs) and their components of

174 status, or major adverse cardiovascular and cerebrovascular events (MACCEs) in older adults undergoi

175 jor adverse cardiovascular events (n = 103), cerebrovascular events (n = 53), graft failure or doubli

176 ian follow-up of 19.6 months, a total of 108 cerebrovascular events occurred (15.7% event rate).

177 No cerebrovascular events occurred in the GSNO group.

178 Major adverse cardiovascular and cerebrovascular events occurred most frequently in patie

179 No in-hospital major adverse cardiac and cerebrovascular events occurred.

180 From January 2000 to December 2002, 2,350 cerebrovascular events occurred.

181 l end points and was effective in preventing cerebrovascular events (odds ratio [OR], 0.61; 95% confi

182 in terms of major adverse cardiovascular and cerebrovascular events of 2 different complete coronary

183 We sought to assess the effects on cerebrovascular events of treating patients with stable

184 Complex plaques were associated with cerebrovascular events only univariately.

185 to first clinical event (renal, cardiac, or cerebrovascular event or death).

186 peri-procedural or major adverse cardiac or cerebrovascular event or need for cardiac surgical inter

187 ny increase in the rate of cardiovascular or cerebrovascular events or related mortality.

188 ta-blocker therapy only reduced the odds for cerebrovascular events (OR, 0.75; 95% CI, 0.57-0.98) but

189 .84-1.29; P=0.73), major adverse cardiac and cerebrovascular events (OR, 1.05; 95% CI, 0.80-1.38; P=0

190 BB measure was not associated with increased cerebrovascular events (OR, 1.22; 95% CI, 0.62-2.38).

191 0.66-1.54) but was associated with increased cerebrovascular events (OR, 3.01; 95% CI, 1.00-10.07).

192 the single strongest factor associated with cerebrovascular events (OR, 4.32; 95% CI, 1.26 to 14.83)

193 fined as death, acute myocardial infarction, cerebrovascular event, or further revascularization at h

194 erebrovascular death, myocardial infarction, cerebrovascular event, or revascularization.

195 y safety end point was a composite of death, cerebrovascular events, or serious treatment-related adv

196 und that 342 of the 119,668 mothers suffered cerebrovascular events over 14-19 years' follow-up.

197 ids had a significant reduction in secondary cerebrovascular events (P = .0049).

198 iated with a 0.6% relative risk reduction in cerebrovascular events (p = 0.002) and a 0.5% relative r

199 ted that LA fibrosis independently predicted cerebrovascular events (p = 0.002) and significantly inc

200 event (a composite of any coronary event, a cerebrovascular event, peripheral vascular disease, or h

201 D events, comprising coronary heart disease, cerebrovascular events, peripheral artery disease, and c

202 1994 and 2000, 308 consecutive patients with cerebrovascular events presumably related to PFO underwe

203 One-year mortality, cerebrovascular events, Q-wave myocardial infarction, ta

204 st that the 1-year major adverse cardiac and cerebrovascular event rate is higher among diabetic pati

205 th CED had a significantly higher cumulative cerebrovascular event rate than those without (P=0.04).

206 The overall 1-year major adverse cardiac and cerebrovascular event rate was higher among diabetic pat

207 unadjusted major adverse cardiovascular and cerebrovascular event rate was reduced with CABG for pat

208 uld be detected on major adverse cardiac and cerebrovascular event rates after BMMNC infusion after a

209 nt in crude major adverse cardiovascular and cerebrovascular event rates at 30 days and 1 year betwee

210 Major adverse cardiac and cerebrovascular event rates at 5 years was 36.9% in PCI

211 mple in which age- and sex-specific ischemic cerebrovascular event rates were determined and in a sam

212 infarct size, and major adverse cardiac and cerebrovascular event rates.

213 year mortality and major adverse cardiac and cerebrovascular events remained consistent in the TO-tre

214 population), whereas the pathophysiology of cerebrovascular events remains largely unknown.

215 has been broadly studied, little is known on cerebrovascular events revealed by out-of-hospital cardi

216 hmia (RR=0.99; 95% CI, 0.85-1.16; P=0.92) or cerebrovascular events (RR=1.03; 95% CI, 0.92-1.16; P=0.

217 55%; 86% of the heterozygotes had recurrent cerebrovascular event(s) and 40% died.

218 New coronary and/or cerebrovascular events served as outcome variables over

219 3602 patients (2.0%) experienced at least 1 cerebrovascular event (stroke: 63 patients; transient is

220 onal hazards regression, we compared risk of cerebrovascular events (stroke, carotid revascularizatio

221 the perinatal and neonatal period, including cerebrovascular events that are diagnosed during the per

222 spectively evaluated for any well documented cerebrovascular events that occurred at > or = 18 years

223 The methods involved ascertaining cerebrovascular events that occurred in Nueces County, T

224 nd points included major adverse cardiac and cerebrovascular events, transient ischemic attack, and d

225 Prediction of major cardiovascular and cerebrovascular events using conventional risk factor mo

226 Ten-year incidence of cerebrovascular events was 34% in patients treated with

227 ereas freedom from major adverse cardiac and cerebrovascular events was 80.9% after SAVR and 67.3% af

228 ow-up, the rate of major adverse cardiac and cerebrovascular events was 9.9% per patient-year, and th

229 The risk of cerebrovascular events was also associated with increase

230 ference in overall major adverse cardiac and cerebrovascular events was found between treatment group

231 uding those with a history of cardiovascular/cerebrovascular events, was 1.75 (95% confidence interva

232 As endothelial activation is a hallmark of cerebrovascular events, we postulated that this may also

233 o, rates of major adverse cardiovascular and cerebrovascular events were 4.2% versus 5.0% among patie

234 ilar results were obtained when coronary and cerebrovascular events were analyzed separately.

235 Cerebrovascular events were associated with significantl

236 d composite major adverse cardiovascular and cerebrovascular events were compared between the CABG an

237 served numbers of first hospitalizations for cerebrovascular events were compared with that expected

238 However, when only the cerebrovascular events were considered, the difference b

239 Major adverse cardiac and cerebrovascular events were defined as the composite of

240 Risk estimates of the presence of IPH for cerebrovascular events were derived in random effects re

241 Among the study population, a total of 25 cerebrovascular events were documented, 22 in patients w

242 Cerebrovascular events were independently predicted by o

243 l and freedom from major adverse cardiac and cerebrovascular events were observed after SAVR compared

244 Cerebrovascular events were often disabling and were str

245 Early major adverse cardiac and cerebrovascular events were reported in 18 (15%) patient

246 Major adverse cardiac and cerebrovascular events were similar between arms in pati

247 Rates of postoperative cerebrovascular events were similar between groups (2.7%

248 ncidence of major adverse cardiovascular and cerebrovascular events, which were defined as cardiac de

249 equivalent major adverse cardiovascular and cerebrovascular event with PCI for 2-vessel (hazard rati

250 d increased major adverse cardiovascular and cerebrovascular event with PCI for patients with 2-vesse

251 tely symptomatic patients ([urgent] ischemic cerebrovascular event within the previous 5 days) underg

252 In HORIZONS-AMI, cerebrovascular events within 3 years after ST-segment-e